Canadian Study of Adherence Outcomes in Adalimumab Patients: Three-Year Results from the COMPANION Study
Author(s): ,
John K. Marshall
Louis Bessette
Gerald Lebovic
Brad Millson
Canadian Pharmacists Conference ePoster Library. Latour M. 06/03/17; 174240; 12
Dr. Martin Latour
Dr. Martin Latour
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)

Adalimumab (ADL) is a TNF-alpha inhibitor indicated for various inflammatory autoimmune diseases. Patients receiving ADL in Canada can enroll in the AbbVie Care patient support program (PSP). This retrospective study assessed the impact of PSP services and patient characteristics on persistence and adherence to ADL over a 3-year period.

Upon probabilistic linkage to the IMS longitudinal pharmacy transaction database (LRx), PSP patients starting ADL between July 2010 and August 2012 were tracked for 36 months to calculate persistence (end if >90 days without therapy). Cox and multivariable logistic regression models provided hazard ratios (HR) and adjusted odds ratios (OR) to measure the association between patient characteristics/PSP services and persistence and adherence, respectively. Adherence was measured using the medication possession ratio (MPR) (>=80% MPR). Persistence analyses over 36 months were done in patients who were persistent up to when specific PSP services were introduced.

In the overall cohort (N=4,772), older age groups had significantly greater odds of adherence (40-49, 50-59, 60-69, 70+; OR=1.3, 1.4, 1.4, 2.1; p<0.05 for all comparisons) relative to the 30-39 years age group. In patients (n=2,866) who were persistent when ongoing care coach calls became available, those receiving this service were 65% less likely to stop therapy (HR=0.35, p<0.01) and 38% more likely to be adherent (OR = 1.38, p<0.01) compared to those without it.

Ongoing care coach calls provided by the AbbVie Care PSP significantly correlate with greater patient persistence and adherence over 36 months. Patients aged between 30 and 39 years appear to have lower adherence compared to older age groups. These results may help refine services that improve treatment adherence.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings